Economic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective.

Med Klin Intensivmed Notfmed · 2025 · PMC12708791 · PMID 39739037

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Beyond direct CAR‐T therapy, the utilization of ICU resources and subsequent follow-up costs may be significant.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.